132 related articles for article (PubMed ID: 38118215)
1. EZH2 as a potential therapeutic target for gastrointestinal cancers.
Hashemi M; Nazdari N; Gholamiyan G; Paskeh MDA; Jafari AM; Nemati F; Khodaei E; Abyari G; Behdadfar N; Raei B; Raesi R; Nabavi N; Hu P; Rashidi M; Taheriazam A; Entezari M
Pathol Res Pract; 2024 Jan; 253():154988. PubMed ID: 38118215
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
[TBL] [Abstract][Full Text] [Related]
4. EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects.
Paskeh MDA; Mehrabi A; Gholami MH; Zabolian A; Ranjbar E; Saleki H; Ranjbar A; Hashemi M; Ertas YN; Hushmandi K; Mirzaei S; Ashrafizadeh M; Zarrabi A; Samarghandian S
Biomed Pharmacother; 2022 Feb; 146():112532. PubMed ID: 34906772
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis.
Sasaki M; Yamaguchi J; Itatsu K; Ikeda H; Nakanuma Y
J Pathol; 2008 Jun; 215(2):175-83. PubMed ID: 18393368
[TBL] [Abstract][Full Text] [Related]
6. Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.
Wan Z; Jiang H; Li L; Zhu S; Hou J; Yu Y
Bioorg Med Chem; 2020 Apr; 28(7):115379. PubMed ID: 32098708
[TBL] [Abstract][Full Text] [Related]
7. The roles of EZH2 in cancer and its inhibitors.
Liu Y; Yang Q
Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.
Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B
Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway.
Kwon H; Song K; Han C; Zhang J; Lu L; Chen W; Wu T
Am J Pathol; 2017 Oct; 187(10):2288-2299. PubMed ID: 28923203
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of enhancer of zeste homolog 2 and MUC1 may be related to malignant behaviour in intraductal papillary neoplasm of the bile duct.
Sasaki M; Matsubara T; Yoneda N; Nomoto K; Tsuneyama K; Sato Y; Nakanuma Y
Histopathology; 2013 Feb; 62(3):446-57. PubMed ID: 23163606
[TBL] [Abstract][Full Text] [Related]
11. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
12. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
14. Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.
Nouruzi S; Tabrizian N; Zoubeidi A
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36718085
[TBL] [Abstract][Full Text] [Related]
15. EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
Tang B; Du J; Li Y; Tang F; Wang Z; He S
Med Oncol; 2014 Nov; 31(11):271. PubMed ID: 25280519
[TBL] [Abstract][Full Text] [Related]
16. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma.
Sasaki M; Ikeda H; Itatsu K; Yamaguchi J; Sawada S; Minato H; Ohta T; Nakanuma Y
Lab Invest; 2008 Aug; 88(8):873-82. PubMed ID: 18591938
[TBL] [Abstract][Full Text] [Related]
17. An immunohistochemical panel of insulin-like growth factor II mRNA-binding protein 3 (IMP3), enhancer of zeste homolog 2 (EZH2), and p53 is useful for a diagnosis in bile duct biopsy.
Sasaki M; Sato Y
Virchows Arch; 2021 Oct; 479(4):697-703. PubMed ID: 34115196
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
20. Functional roles of enhancer of zeste homolog 2 in gliomas.
Yin Y; Qiu S; Peng Y
Gene; 2016 Jan; 576(1 Pt 2):189-94. PubMed ID: 26435191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
